Galenica sales rise 5.7% to CHF 3.17 billion in first nine months of 2026
Swiss group Galenica lifted sales 5.7% to CHF 3.17 billion in the first nine months of 2026 and confirmed its full-year outlook, Reuters reported.
- published on Newsmetry
- original source published
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner. connect the api →
what happened
Swiss company Galenica AG said its sales for the first nine months of 2026 rose 5.7% to CHF 3.17 billion. The company also confirmed its outlook for the full year 2026. Reuters reported the information citing the company's statement.
The pharmacy segment, which covers omni-channel sales, grew 6.2% to CHF 1.13 billion, with organic growth of 4.5%. The products and brands division moved the other way, falling 7.2% to CHF 136.5 million. Services and production sales increased 5.8% to CHF 93.6 million.
why it matters
For investors the update signals that the group's growth is holding up, with the pharmacy business still the main driver of revenue. The decline in products and brands shows that performance varies across the company.
tags
instruments
sources
- Galenica Sales Up 5.7% To CHF 3.17 Bln In First Nine Months Of 2026, Confirms Outlook — Reuters, 22 October 2026 at 04:45 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner.
get stories in real time ↗